Osaka, Japan, August 31st, 2026 - Luxna Biotech Co., Ltd. President & CEO: Hideaki Sato, Headquarters: Suita-shi, Osaka, Japan, hereinafter “Luxna”) today announced that it has entered into a collaborative research agreement with a license option with Servier (President: Olivier Laureau; Headquarters: Suresnes, France; hereinafter “Servier”), an independent international pharmaceutical company governed by a Foundation.
The Agreement
includes an option for Servier to obtain worldwide exclusive license to Luxna
XNAs Technology and provides the framework for continued collaborative research
and the further strengthening of the strategic relationship between the
companies.
Luxna Biotech
and Servier initiated a collaborative drug discovery program (“the Program”) in
April 2024 to optimize antisense oligonucleotide lead compounds targeting
neurological diseases using Luxna XNAs Technology. Following the achievement of
the first-stage milestone, Luxna Biotech has become eligible to receive a
milestone payment from Servier.
Upon
achievement of the next stage, Luxna will be eligible for additional milestone
payments. The parties may enter into a worldwide exclusive license agreement
granting Servier exclusive rights to Luxna XNAs Technology. If executed, the
license agreement will provide Luxna with an upfront payment, annual fees, and
milestone payments.
Hideaki Sato,
President & CEO of Luxna, commented as follows: “We have been pursuing the application of
Luxna XNAs Technology to the field of neurological diseases and have
strengthened our platform for generating optimal ASOs for CNS indications. We
are very pleased that we have progressed from collaborative research to an
Option Agreement, which reflects an expansion of our strategic alliance with
Servier. This partnership with Servier will further accelerate the development
and practical application of oligonucleotide therapies using Luxna XNAs
Technology.”
About
Luxna XNAs Technology Luxna
XNAs Technology collectively means an innovative nucleic acid group of AmNA™,
scpBNA™, GuNA™ and 5’-CP™ originated in Professor Obika’s laboratory at the
Osaka University Graduate School of Pharmaceutical Sciences, Bioorganic
Chemistry. Luxna XNAs Technology could make available ASOs with high activity
and low toxicity, by taking advantage of its characteristics of strong binding
to mRNA and/or reduced toxicity.
About
Luxna Biotech
Co., Ltd. Luxna
is a biotech founded to develop safer and more effective oligonucleotide
therapies (OTs) for practical use using the drug discovery platform based on
modified nucleic acids originated at Osaka University. Our purpose is to bring OTs
for patients with difficult-to-treat diseases. We actively collaborate with several
pharmaceutical companies in developing new and effective OTs as well as
advancing our own.
Contact Luxna Biotech Co., Ltd. E-mail: info@luxnabiotech.co.jp Website : https://luxnabiotech.co.jp/
